Research map: Redifferentiation-enabled TSHRCART cells overcome antigen loss in aggressive thyroid cancers

Back to the article

Papers in this map

  1. Tissue-based map of the human proteome · Mathias Uhlén · 2015 · 16361 citations · Cited by this paper
  2. AcTor, a novel mTOR stimulator, potentiates ixazomib for the treatment of acute myeloid leukemia · 2026 · Related
  3. CAR-T cell therapy: current limitations and potential strategies · Robert C. Sterner · 2021 · 2926 citations · Cited by this paper
  4. Breaking the immune “cold niche” in bone metastasis: core mechanisms of the multidimensional interwoven regulatory network and precision breakthrough strategies · 2026 · Related
  5. Tumor Antigen Escape from CAR T-cell Therapy · Robbie G. Majzner · 2018 · 1213 citations · Cited by this paper
  6. Landscape of T-cell bispecific antibodies in cancer therapy: therapeutic strategies, challenges and future prospection · 2026 · Related
  7. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600–Mutant Anaplastic Thyroid Cancer · Vivek Subbiah · 2017 · 903 citations · Cited by this paper
  8. Trace elements and tumors: homeostatic networks, molecular mechanisms and new horizons for precision intervention · 2026 · Related
  9. Selumetinib-Enhanced Radioiodine Uptake in Advanced Thyroid Cancer · Alan Loh Ho · 2013 · 849 citations · Cited by this paper
  10. Autophagy in cancer — functional plasticity, therapeutic paradox, and the road to precision modulation: a comprehensive review · 2026 · Related
  11. CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape · Mohamad Hamieh · 2019 · 681 citations · Cited by this paper
  12. Multimodal sequencing identifies synergistic mechanisms driving resistance to neoadjuvant nivolumab treatment in hepatocellular carcinoma · 2026 · Related
  13. GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts · Rosalie M. Sterner · 2018 · 641 citations · Cited by this paper
  14. Reprogramming the pancreatic ductal adenocarcinoma microenvironment: a novel integrin-targeted cytotoxin, ProAgio, potentiates chemotherapy · 2026 · Related
  15. Mutational Profile of Advanced Primary and Metastatic Radioactive Iodine-Refractory Thyroid Cancers Reveals Distinct Pathogenetic Roles for BRAF, PIK3CA , and AKT1 · Julio C. Ricarte‐Filho · 2009 · 531 citations · Cited by this paper
  16. ADSL drives fumarate mediated scrib-rictor complex formation to promote metastasis dissemination in triple-negative breast cancer · 2026 · Related
  17. BRAF Inhibition Increases Tumor Infiltration by T cells and Enhances the Antitumor Activity of Adoptive Immunotherapy in Mice · Chengwen Liu · 2012 · 383 citations · Cited by this paper
  18. Liposomal drug delivery for lung cancer therapy: progress, challenges, and future perspectives · 2026 · Related
  19. Tumor heterogeneity reshapes the tumor microenvironment to influence drug resistance · Aiping Zhang · 2022 · 363 citations · Cited by this paper
  20. The influence of hypoxia on cancer lipid metabolism: a scoping review · 2026 · Related
  21. Cancer cell plasticity during tumor progression, metastasis and response to therapy · Andrea Pérez-González · 2023 · 348 citations · Cited by this paper
  22. CAR T cell therapy and the tumor microenvironment: Current challenges and opportunities · Lionel Aurelien Kankeu Fonkoua · 2022 · 281 citations · Cited by this paper
  23. Suppression of BRAF/MEK/MAP Kinase Pathway Restores Expression of Iodide-Metabolizing Genes in Thyroid Cells Expressing the V600E BRAF Mutant · Dingxie Liu · 2007 · 202 citations · Cited by this paper
  24. A TCF4-dependent gene regulatory network confers resistance to immunotherapy in melanoma · Joanna Poźniak · 2024 · 201 citations · Cited by this paper
  25. CAR-T Therapies in Solid Tumors: Opportunities and Challenges · Grace Guzman · 2023 · 198 citations · Cited by this paper
  26. Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies · Iñigo Landa · 2019 · 197 citations · Cited by this paper
  27. Biologic and Clinical Perspectives on Thyroid Cancer · Somayyeh Fahiminiya · 2016 · 175 citations · Cited by this paper
  28. Phase II Efficacy and Pharmacogenomic Study of Selumetinib (AZD6244; ARRY-142886) in Iodine-131 Refractory Papillary Thyroid Carcinoma with or without Follicular Elements · David Neil Hayes · 2012 · 149 citations · Cited by this paper
  29. Targeting cancer-associated fibroblasts in the bone marrow prevents resistance to CART-cell therapy in multiple myeloma · Reona Leo Sakemura · 2022 · 147 citations · Cited by this paper
  30. Durable Remissions in Children with Relapsed/Refractory ALL Treated with T Cells Engineered with a CD19-Targeted Chimeric Antigen Receptor (CTL019) · Stephan A. Grupp · 2015 · 140 citations · Cited by this paper
  31. A novel source of viable peripheral blood mononuclear cells from leukoreduction system chambers · Allan B. Dietz · 2006 · 136 citations · Cited by this paper
  32. Role of MAPK pathway oncoproteins in thyroid cancer pathogenesis and as drug targets · Jeffrey A. Knauf · 2009 · 135 citations · Cited by this paper
  33. Human Thyroid Tumor Cell Lines Derived from Different Tumor Types Present a Common Dedifferentiated Phenotype · Wilma C.G. van Staveren · 2007 · 125 citations · Cited by this paper
  34. Molecular and Genotypic Characterization of Human Thyroid Follicular Cell Carcinoma–Derived Cell Lines · Ana Margarida Meireles · 2007 · 106 citations · Cited by this paper
  35. TSH receptor specific monoclonal autoantibody K1‐70TM targeting of the TSH receptor in subjects with Graves' disease and Graves' orbitopathy—Results from a phase I clinical trial · Jadwiga Furmaniak · 2022 · 99 citations · Cited by this paper
  36. Human Thyroid Cancer: Membrane Thyrotropin Binding and Adenylate Cyclase Activity · Pierre Carayon · 1980 · 96 citations · Cited by this paper
  37. Driving cars to the clinic for solid tumors · Mauro L. Castellarin · 2018 · 91 citations · Cited by this paper
  38. Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment · Gregory Lawrence Beatty · 2014 · 85 citations · Cited by this paper
  39. Potential Utility and Limitations of Thyroid Cancer Cell Lines as Models for Studying Thyroid Cancer · Tania Pilli · 2009 · 83 citations · Cited by this paper

Source: OpenAlex (CC0)